111 Capital Relay Therapeutics, Inc. Transaction History
111 Capital
- $582 Billion
- Q2 2025
A detailed history of 111 Capital transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, 111 Capital holds 24,911 shares of RLAY stock, worth $92,419. This represents 0.01% of its overall portfolio holdings.
Number of Shares
24,911Holding current value
$92,419% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding RLAY
# of Institutions
222Shares Held
163MCall Options Held
153KPut Options Held
49.2K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$104 Million0.67% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.1MShares$44.9 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct10.8MShares$40.2 Million0.07% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$39.1 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY9.1MShares$33.8 Million2.79% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $446M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...